CA1284640C - Therapeutic compositions based on 3-alkoxyflavone derivatives, and novel 3-alkoxyflavone derivatives - Google Patents
Therapeutic compositions based on 3-alkoxyflavone derivatives, and novel 3-alkoxyflavone derivativesInfo
- Publication number
- CA1284640C CA1284640C CA000527372A CA527372A CA1284640C CA 1284640 C CA1284640 C CA 1284640C CA 000527372 A CA000527372 A CA 000527372A CA 527372 A CA527372 A CA 527372A CA 1284640 C CA1284640 C CA 1284640C
- Authority
- CA
- Canada
- Prior art keywords
- hydroxy
- group
- alkoxy
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 12
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 12
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 60
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 49
- 229910052739 hydrogen Inorganic materials 0.000 claims description 43
- 239000001257 hydrogen Substances 0.000 claims description 43
- -1 methylenedioxy Chemical group 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 28
- 125000003051 glycosyloxy group Chemical group 0.000 claims description 25
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 10
- SSXJHQZOHUYEGD-UHFFFAOYSA-N 3-Methoxynobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 SSXJHQZOHUYEGD-UHFFFAOYSA-N 0.000 claims description 9
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000007717 exclusion Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 35
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 11
- 235000013350 formula milk Nutrition 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 19
- 238000000034 method Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Chemical class O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 231100000636 lethal dose Toxicity 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- CDQGCHBSQIWYES-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-3-methoxychromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(OC)=C1C1=CC=C(O)C=C1 CDQGCHBSQIWYES-UHFFFAOYSA-N 0.000 description 3
- GKWVFAJEXKBCSA-UHFFFAOYSA-N 3-methoxy-2-(4-phenylmethoxyphenyl)chromen-4-one Chemical class O1C2=CC=CC=C2C(=O)C(OC)=C1C(C=C1)=CC=C1OCC1=CC=CC=C1 GKWVFAJEXKBCSA-UHFFFAOYSA-N 0.000 description 3
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 235000005513 chalcones Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- SZXZDCMOSSADOV-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-3-methoxy-7-methylchromen-4-one Chemical compound O1C2=CC(C)=CC=C2C(=O)C(OC)=C1C1=CC=C(O)C=C1 SZXZDCMOSSADOV-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- MIRRKSIIJPBULL-UHFFFAOYSA-N 3,6-dimethoxy-2-(4-methoxyphenyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=CC(OC)=CC=C2O1 MIRRKSIIJPBULL-UHFFFAOYSA-N 0.000 description 2
- WEDXXKDDCBFJNI-UHFFFAOYSA-N 7-fluoro-2-(4-hydroxyphenyl)-3-methoxychromen-4-one Chemical compound O1C2=CC(F)=CC=C2C(=O)C(OC)=C1C1=CC=C(O)C=C1 WEDXXKDDCBFJNI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 150000001789 chalcones Chemical class 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- SXCVUHOMRYMCHH-WEVVVXLNSA-N (e)-1-(2-hydroxy-5-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1\C=C\C(=O)C1=CC(OC)=CC=C1O SXCVUHOMRYMCHH-WEVVVXLNSA-N 0.000 description 1
- RGPGOSUTRORKLZ-DHZHZOJOSA-N (e)-1-(2-hydroxy-6-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1\C=C\C(=O)C1=C(O)C=CC=C1OC RGPGOSUTRORKLZ-DHZHZOJOSA-N 0.000 description 1
- TTWITESQDJUURJ-XVNBXDOJSA-N (e)-1-(5-chloro-2-hydroxyphenyl)-3-(4-chlorophenyl)prop-2-en-1-one Chemical compound OC1=CC=C(Cl)C=C1C(=O)\C=C\C1=CC=C(Cl)C=C1 TTWITESQDJUURJ-XVNBXDOJSA-N 0.000 description 1
- BVKPRMYQBQPMLS-UHFFFAOYSA-N 1-(2-hydroxy-3-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C=CC(=O)C1=CC=CC(OC)=C1O BVKPRMYQBQPMLS-UHFFFAOYSA-N 0.000 description 1
- OXJNAMHGUAYTFA-UHFFFAOYSA-N 1-(2-hydroxy-4-phenylmethoxyphenyl)-3-(4-phenylmethoxyphenyl)prop-2-en-1-one Chemical compound C=1C=C(C(=O)C=CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(O)=CC=1OCC1=CC=CC=C1 OXJNAMHGUAYTFA-UHFFFAOYSA-N 0.000 description 1
- PQZKTWBQDPHGOU-UHFFFAOYSA-N 1-(2-hydroxyphenyl)-3-(4-phenylmethoxyphenyl)prop-2-en-1-one Chemical compound OC1=CC=CC=C1C(=O)C=CC(C=C1)=CC=C1OCC1=CC=CC=C1 PQZKTWBQDPHGOU-UHFFFAOYSA-N 0.000 description 1
- PVEXJEITSZPXNK-UHFFFAOYSA-N 1-(4-chloro-2-hydroxyphenyl)-3-(4-chlorophenyl)prop-2-en-1-one Chemical compound OC1=CC(Cl)=CC=C1C(=O)C=CC1=CC=C(Cl)C=C1 PVEXJEITSZPXNK-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- ROFQUNWTHFYWMD-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-3,5-dimethoxychromen-4-one Chemical compound COC=1C(=O)C=2C(OC)=CC=CC=2OC=1C1=CC=C(O)C=C1 ROFQUNWTHFYWMD-UHFFFAOYSA-N 0.000 description 1
- HOFBGBOPKGNQBZ-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-3,6-dimethoxychromen-4-one Chemical compound COC=1C(=O)C2=CC(OC)=CC=C2OC=1C1=CC=C(O)C=C1 HOFBGBOPKGNQBZ-UHFFFAOYSA-N 0.000 description 1
- KSAJJMQNUNAUAD-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-3,8-dimethoxychromen-4-one Chemical compound COC1=CC=CC(C(C=2OC)=O)=C1OC=2C1=CC=C(O)C=C1 KSAJJMQNUNAUAD-UHFFFAOYSA-N 0.000 description 1
- ZWVHTXAYIKBMEE-UHFFFAOYSA-N 2-hydroxyacetophenone Chemical compound OCC(=O)C1=CC=CC=C1 ZWVHTXAYIKBMEE-UHFFFAOYSA-N 0.000 description 1
- PBEJTRAJWCNHRS-UHFFFAOYSA-N 2-phenylmethoxybenzaldehyde Chemical compound O=CC1=CC=CC=C1OCC1=CC=CC=C1 PBEJTRAJWCNHRS-UHFFFAOYSA-N 0.000 description 1
- MEYWLJLCTUCUSG-UHFFFAOYSA-N 3,8-dimethoxy-2-(4-methoxyphenyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=CC=CC(OC)=C2O1 MEYWLJLCTUCUSG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FHXDSQYFCFWKAW-UHFFFAOYSA-N 3-chloro-2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(Cl)=C1C1=CC=CC=C1 FHXDSQYFCFWKAW-UHFFFAOYSA-N 0.000 description 1
- DLXHBDRJDYJURK-UHFFFAOYSA-N 3-hydroxy-2-(4-methoxyphenyl)-6-phenylmethoxychromen-4-one Chemical compound OC1=C(OC2=CC=C(C=C2C1=O)OCC1=CC=CC=C1)C1=CC=C(C=C1)OC DLXHBDRJDYJURK-UHFFFAOYSA-N 0.000 description 1
- HYCPSIKUWOEHAR-UHFFFAOYSA-N 3-hydroxy-2-(4-phenylmethoxyphenyl)chromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(O)=C1C(C=C1)=CC=C1OCC1=CC=CC=C1 HYCPSIKUWOEHAR-UHFFFAOYSA-N 0.000 description 1
- RIRAMOVDGJDPRU-UHFFFAOYSA-N 3-hydroxy-6-methoxy-2-(4-methoxyphenyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=CC(OC)=CC=C2O1 RIRAMOVDGJDPRU-UHFFFAOYSA-N 0.000 description 1
- ZAIANDVQAMEDFL-UHFFFAOYSA-N 3-methoxy-2-phenylchromen-4-one Chemical class O1C2=CC=CC=C2C(=O)C(OC)=C1C1=CC=CC=C1 ZAIANDVQAMEDFL-UHFFFAOYSA-N 0.000 description 1
- LPACBRAWRCXZGB-UHFFFAOYSA-N 3-methyl-2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(C)=C1C1=CC=CC=C1 LPACBRAWRCXZGB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- DDNPCXHBFYJXBJ-UHFFFAOYSA-N 5,7-dihydroxy-2-(4-hydroxyphenyl)-3,6-dimethoxychromen-4-one Chemical compound COC=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=C(O)C=C1 DDNPCXHBFYJXBJ-UHFFFAOYSA-N 0.000 description 1
- JDVPHCLYMGBZLE-UHFFFAOYSA-N 5-Hydroxy-3,3',4',6,7,8-hexamethoxyflavone Chemical compound C1=C(OC)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(OC)C(OC)=C2O1 JDVPHCLYMGBZLE-UHFFFAOYSA-N 0.000 description 1
- YSXFFLGRZJWNFM-UHFFFAOYSA-N 5-hydroxy-2-(4-hydroxyphenyl)-3,6,7-trimethoxychromen-4-one Chemical compound COC=1C(=O)C=2C(O)=C(OC)C(OC)=CC=2OC=1C1=CC=C(O)C=C1 YSXFFLGRZJWNFM-UHFFFAOYSA-N 0.000 description 1
- CUGDYSSBTWBKII-UHFFFAOYSA-N 6-(dimethylamino)hexane-1,2,3,4,5-pentol Chemical compound CN(C)CC(O)C(O)C(O)C(O)CO CUGDYSSBTWBKII-UHFFFAOYSA-N 0.000 description 1
- IBVFRLPIMVRDDY-UHFFFAOYSA-N 6-chloro-2-(4-chlorophenyl)-3-hydroxychromen-4-one Chemical compound O1C2=CC=C(Cl)C=C2C(=O)C(O)=C1C1=CC=C(Cl)C=C1 IBVFRLPIMVRDDY-UHFFFAOYSA-N 0.000 description 1
- LPXSAPZRLTYHQZ-UHFFFAOYSA-N 6-chloro-2-(4-hydroxyphenyl)-3-methoxychromen-4-one Chemical compound O1C2=CC=C(Cl)C=C2C(=O)C(OC)=C1C1=CC=C(O)C=C1 LPXSAPZRLTYHQZ-UHFFFAOYSA-N 0.000 description 1
- UPZKOXZROOTBEV-UHFFFAOYSA-N 6-hydroxy-2-(4-hydroxyphenyl)-3-methoxychromen-4-one Chemical compound O1C2=CC=C(O)C=C2C(=O)C(OC)=C1C1=CC=C(O)C=C1 UPZKOXZROOTBEV-UHFFFAOYSA-N 0.000 description 1
- JBIILNIOLNVMJO-UHFFFAOYSA-N 6-hydroxy-3-methoxy-2-(4-methoxyphenyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=CC(O)=CC=C2O1 JBIILNIOLNVMJO-UHFFFAOYSA-N 0.000 description 1
- OFHWYDPRLMIIDM-UHFFFAOYSA-N 7-chloro-3-hydroxy-2-(4-methoxyphenyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=CC=C(Cl)C=C2O1 OFHWYDPRLMIIDM-UHFFFAOYSA-N 0.000 description 1
- 238000006188 Allan-Robinson condensation reaction Methods 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- UXUFMIJZNYXWDX-UHFFFAOYSA-N Flavokawain C Natural products COC1=CC(OC)=CC(O)=C1C(=O)C=CC1=CC=C(O)C=C1 UXUFMIJZNYXWDX-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 241000605411 Lloydia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000004185 countercurrent chromatography Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Therapeutic compositions based on 3-alkoxyflavone deriva-tives, and novel 3-alkoxyflavone derivatives ABSTRACT OF THE DISCLOSURE
The present invention relates to therapeutic compositions based on 3-alkoxyflavone derivatives, which have in particular an antiviral activity.
Figures: none
The present invention relates to therapeutic compositions based on 3-alkoxyflavone derivatives, which have in particular an antiviral activity.
Figures: none
Description
The present invention relates to therapeutic compositions based on 3-alkoxyElavone derlvatives, which have in particular an antiviral activity.
3-Alkoxyflavone derivatives are compounds having the following basic structure:
`r in which Ro is an alkyl group.
European Patent 0 019 081 described 3-alkoxy-flavone derivatives possessing an antiviral activity.
The derivatives have a hydroxyl group or a derived group in the 5-position and a hydroxyl or alkoxy group in the 7-position, the 6-position and 8-position being unsub-stituted. These compounds are described as inhibiting the reproduction of rhinoviruses, enteroviruses, coxsackieviruses and polioviruses.
Nevertheless, some of these 3-alkoxyflavones have relatively low cytotoxic dose/active dose ratios, prohibiting any practical therapeutic application.
Others have even proved inactive.
It has now been found that certain particular classes of 3-alkoxyflavones have a substantial antiviral activity with cytotoxic dose/active dose ratios which permit therapeutic application.
The présent invention thus relates to a thera'peutic composition containing an effective amount of a compound of the formula :
R G ~ 3J R
R O
in which:
R is a C1-C4 alkyl group and 1) R1, R2, R3 and R4 are selected from the group com--prising a hydrogen atom, a halogen atom, a nitro group, a cyano group, a trifluoromethyl group, a C1-C4 alkyl group, a C1-C4 alkoxy group, a benzyloxy group, a methylenedioxy group, a C1-C4 alkanoyl group, a (C1-C4 alkoxy)carbonyloxy group, an amino group, a (C1-C4 alkyl)-amino group, a di(Cl-C4 alkyl)amino group, a (C1-C4 alkanoyl)amino group, a hydroxy group, a (C1-C4 alkanoyl)-oxy group, a glycosyloxy group, a carboxy group and a (C1-C4 alkoxy)carbonyl group, R5, R6, R8 and Rg are selected from the group comprising a hydrogen atom, a halogen atom, a hydroxy group, a C1-C4 alkoxy group, a benzyloxy group and a C1-C4 alkyl group, at least one.of the groups R1, R2, R3, R4, R5, R6, R8 ~nd R9 belng other than a hvdrogen atom, a hydrox~ grou~ or a C1-C4 alkoxy group, for example a halogen atom or a C1-C4 alkyl group, and R7 is a hydroxy or glycosyloxy group;
3-Alkoxyflavone derivatives are compounds having the following basic structure:
`r in which Ro is an alkyl group.
European Patent 0 019 081 described 3-alkoxy-flavone derivatives possessing an antiviral activity.
The derivatives have a hydroxyl group or a derived group in the 5-position and a hydroxyl or alkoxy group in the 7-position, the 6-position and 8-position being unsub-stituted. These compounds are described as inhibiting the reproduction of rhinoviruses, enteroviruses, coxsackieviruses and polioviruses.
Nevertheless, some of these 3-alkoxyflavones have relatively low cytotoxic dose/active dose ratios, prohibiting any practical therapeutic application.
Others have even proved inactive.
It has now been found that certain particular classes of 3-alkoxyflavones have a substantial antiviral activity with cytotoxic dose/active dose ratios which permit therapeutic application.
The présent invention thus relates to a thera'peutic composition containing an effective amount of a compound of the formula :
R G ~ 3J R
R O
in which:
R is a C1-C4 alkyl group and 1) R1, R2, R3 and R4 are selected from the group com--prising a hydrogen atom, a halogen atom, a nitro group, a cyano group, a trifluoromethyl group, a C1-C4 alkyl group, a C1-C4 alkoxy group, a benzyloxy group, a methylenedioxy group, a C1-C4 alkanoyl group, a (C1-C4 alkoxy)carbonyloxy group, an amino group, a (C1-C4 alkyl)-amino group, a di(Cl-C4 alkyl)amino group, a (C1-C4 alkanoyl)amino group, a hydroxy group, a (C1-C4 alkanoyl)-oxy group, a glycosyloxy group, a carboxy group and a (C1-C4 alkoxy)carbonyl group, R5, R6, R8 and Rg are selected from the group comprising a hydrogen atom, a halogen atom, a hydroxy group, a C1-C4 alkoxy group, a benzyloxy group and a C1-C4 alkyl group, at least one.of the groups R1, R2, R3, R4, R5, R6, R8 ~nd R9 belng other than a hvdrogen atom, a hydrox~ grou~ or a C1-C4 alkoxy group, for example a halogen atom or a C1-C4 alkyl group, and R7 is a hydroxy or glycosyloxy group;
2) Rl, R2, R3 and R4 are selected from the group comprising a hydroxy group and a C1-C4 alkoxy group, R5, R6,R8 and Rg are selected from the group comprising a hydrogen atom~a hydroxy group and a Cl-C4 alkoxy group, and R7 is a hydroxy, C1-C4 alkoxy o~ glycosyloxy.qroup, with the exclusion of 3,3', 4' , 5,6,7,8-heptamethoxyflavone ;
1284~
or 3) R1, R2, R3 and R4 are selected from the group com-prising a hydrogen atom, a hydroxy group and a C~-C4 . alkoxy group, three of these groups being other than hydrogen, R5 and Rg are selected from the group comprising a hydrogen atom, a hydroxy group and a C1-C4 alkoxy group, R6 and R8 are hydrogen atoms, and 10 R7 is a hydroxy, a cl-c4 a~oxy ~roU2 or ~ cos~lo~ group;
or 4) R3 and R4 are hydrogen atoms, R1 and R2 are selected from the group comprising a hydroxy group and a C1-C4 alkoxy group, R5, R6, R8 and R9 are selected from the group comprising a hydrogen atom, a hydroxy group and a C1-C4 alkoxy group, and R7 is a hydroxy , C~-C4 alkoxy or glycosyloxy group;
or 5) R~ and R4 are hydrogen atoms, R2 and R~ are selected from the group comprising a hydroxy group and a C1 -C4 alkoxy group, R5, R6, R8 and Rg are selected from the group comprising a hydrogen atom, a hydroxy group and a C~-C4 alkoxy group, and R7 is a hydroxy . C1-C4 alkoxy or glycosyloxy group;
or 6) R3 is a hydrogen atom, Rl, R2 and R4 are selected from the group comprising a hydrogen atom, a hydroxy group and a Cl-C4 alkoxy group, two of these groups being other than hydrogen, R5, R6, R8 and Rg are selected from the group comprising a hydrogen atom, a hydroxy group and a Cl-C4 alkoxy group, and R7 is a hydroxy , Cl-C4 alkoxy or glycosyloxy group;
or 7) Rl, R2, R3 and R4 are selected from the group com-prising a hydrogen atom, a hydroxy group and a C1-C4 alkoxy group, at least three of these groups being a hydrogen atom, R5, R6, R8 and Rg are selected from the group com-prising a hydrogen atom, a hydroxy group and a Cl-C4 alkoxy group, and R7 is a hydroxy , C1-C4 alkoxy or glycosyloxy 10 qroup, ora pharmaceutically acceptable salt thereof.
In the above definition, the expression "a halogen atom" denotes a chlorine, bromine, iodine or fluorine atom.
Pharmaceutically acceptable salts are the addition salts which the compounds form with pharma-ceutically acceptable acids, as well as the salts which the compounds containing an acid group (COOH) form with pharmaceutically acceptable bases.
The expression "addition salts with pharma-ceutically acceptable acids" denotes salts which givethe biological properties of the free bases without having any undesirable effects. In particular, these salts can be those formed with mineral acids such as hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid and phosphoric acid, with metal salts con-taining acid hydrogens, such as disodium orthophosphate and monopotassium sulphate, and with organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, oxalic acid, fumaric acid, lactic acid, succinic acid, tartaric acid and pamoic acid.
Likewise, the expression "salts with pharma-ceutically acceptable bases" denotes salts which do not modify the biological properties of the free acids. In particular, these salts can be those formed with in-organic bases such as sodium hydroxide, potassium ~284~
-- 5 ~
hydroxide, lithium hydroxide, calcium hydroxide andmagnesium hydroxide, or with organic baseS such as glucamine, N-methylglucamine, N~N-dimethylglucamine~
ethanolamine, diethanolamine, morpholine, N-methyl-morpholine and tris(hydroxymethyl)methylamine.
To the knowledge of the Applicant Company, thecompounds of the formula I belonging to the class defined under 1) are novel compounds.
The compounds belonging to the classes defined under 2) to 7) are products of natural origin or derivatives of products of natural origin.
The Applicant Company has also found that 3,3', 4',5,6,7,8-heptamethoxyflavone has an antiviral activity.
The compound was described in US-A-3 867 541 as havina an aggregation-inhibiting activity, with no suggestion of a viral activity. The invention also relates to the use of this compound for the manu-facture of a pharmaceutical composition for treating viral diseases.
In general terms, the 3-alkoxyflavones used in the present invention can be obtained by one of the following processes:
1) Alkylation of 3-hydroxyflavones according to the following scheme:
~3 ~ ~ 7 III
l RZ
~284640 3 ~ J ~ ~ 37 in which Z is a nucleus-repelling group.
Methyl sulphate, methyl iodide or diazomethane may be mentioned as examples of methylating agents.
2) Synthesis by the Allan-Robinson method (J. Chem. Soc.
125, 2192, 1924), in which o-hydroxyaryl ketones are condensed with aromatic acid anhydrides according to the following scheme:
A2~CO-CH2_oQ ~ ~ ~ >
X XI
2 ~
In this method, any hydroxy groups present can be protected, if necessary, and deprotected after the reaction.
~Z846~0 As a variant, using the same type of reaction, it is possible to prepare a 3-hydroxyflavone and then carry out an alkylation as described in 1.
3) The Algar-Flynn-Oyamada oxidation metho~ (J. Algar, J.P. Flynn, Proc. Roy. Irish Acad. 423, 1, 1934; B.
Oyamada, J. Chem. Soc. Japan 55, 1256, 1934), which consists in oxidizing chalcones with hydrogen peroxide in an alkaline medium, this being followed by an alkylation reaction as described in 1, according to the following scheme:
~3 ~ IIH ~R~ II
Rl I
j alkylat~on 3~ ~ 7 ~za4~o In this method, any hydroxy~ groups present can be protected and deprotected at the end.
4) The nuclear reduction of an ester, for example according to the following reaction scheme:
HO = R7 XIV
Rl O
l~ ClY
R4 R ~ R6 ~ `1~ )--2 ~ OR I ~ R
1H2 /Raney Ni ~2 ~ ; R7 XVI
1;2B46~0 Y being, for example, a p-toluenesulphonyl radical.
5) Nuclear oxidation, for example with persulphate, according to the following scheme:
~3 = ~7 Rl O
oxidation ~ /
~3 ~ ; ~ ~7 Rl O
A number of 3-alkoxyflavones which can be used in the present invention are present in plants and can be obtained by extraction.
The extraction method is as follows:
The leaves of the plants are macerated with 80~ ethanol at room temperature for 2 hours, with stirring. After maceration, the leaves are filtered off and the filtra-tion residue is percolated with the same solvent. The filtrate and the percolation liquid are combined and concentrated in vacuo (at a temperature below 40C) to give a thick extract. The extract is partitioned between 90% methanol and hexane (or a 40-60 petroleum ether).
The methanol phase is separated off and evaporated to dryness. The residue obtained is partitioned between l2s464al water (pH 5) and ethyl acetate. The etHyl acetate phase is separated off and evaporated to dryness. The residue obtained is subjected to countercurrent chroma-tography, dropwise, using a chloroform/water/methanol mixture (7:8:13) as the eluent by the descending tech-nique. The effluent is monitored at 355 nm and by thin layer chro~atography or by high performance liquid chromatography, and the antiviral activity of the fractions is tested. The fractions with antiviral activity are evaporated and then chromatographed on Sephadex~LH 20 using methanol as the eluent, and the eluate is monitored as before. The active fractions are chromatographed on a column of silica gel impregna-ted with 5% of water, a hexane/ethyl acetate/acetic acid mixture (5:3:1) being used as the developer in accordance with the "dry column" technique. This gives the pure active 3-alkoxyflavones.
The examples which follow illustrate the prepara-tion of the compounds of the formula I.
Example: Preparation of 4'-hydroxy-3-methoxyflavone (Algar-Flynn-Oyamada method) a) Preparation of 2'-hydroxy-4-benzyloxychalcone A solution of 2-hydroxyacetophenone (25 mmol) and benzyloxybenzaldehyde (25 mmol) in 25 ml of ethanol is cooled with ice. A 50% solution of potassium hydroxide (25 ml) is added slowly and the mixture is stirred for 4 days at room temperature. The solution is again cooled with ice and acidified with dilute hydrochloric acid. The precipitate is filtered off, washed with water and recrystallized from ethanol (yield: 59%). M.p. = 112-113C.
Other chalcones are prepared in the same way:
* 7`~ /c ~
l;~B4~
Table I
Yield M.p. (C) %
2'-hydroxy-4-benzyloxy-6'-methoxy-chalcone S0 111-112 2'-hydroxy-4-benzyloxy-5'-methoxy-chalcone 50 142-143 2'-hydroxy-4-benzyloxy-4'-methoxy-chalcone 35 123-124 2'-hydroxy-3'-methoxy-4-benzyloxy-chalcone ~ 45 152-153 2'-hydroxy-4,5'-dibenzyloxychalcone 59 121-122 2'-hydroxy-4,4'-dibenzyloxychalcone 55 134-136 2'-hydroxy-4-benzyloxy-5'-chloro-chalcone 88 100-102 2'-hydroxy-4-benzyloxy-4'-chloro-chalcone 40 140-141 2'-hydroxy-4,6'-dimethoxychalcone 58 98-100 2'-hydroxy-4,5'-dimethoxychalcone 78 63-64 2'-hydroxy-3',4-dimethoxychalcone 74 118 2'-hydroxy-4-methoxy-6'-benzyloxy-chalcone 55 75-76 2'-hydroxy-4-methoxy-5'-benzyloxy-chalcone 72 89-92 2'-hydroxy-4-methoxy-5'-chlorochalcone40 191-192 2'-hydroxy-4-methoxy-4'-chlorochalcone68 128-129 2'-hydroxy-4-chloro-6'-methoxychalcone50 116-111 2'-hydroxy-4,5'-dichlorochalcone 60 188-189 2'-hydroxy-4,4'-dichlorochalcone 80 150-151 2'-hydroxy-4-benzyloxy-5'-methyl-chalcone 53 139 2'-hydroxy-4-benzyloxy-4'-methyl-chalcone 52 144-145 2'-hydroxy-4-benzyloxy-4'-fluoro-chalcone 75 119-120 lZ846410 2'-hydroxy-3'-methyl-4-benzyloxy-5'-chlorochalcone 85 153-154 2'-hydroxy-4-chloro-4'-methylchalcone 55 145 , b) Preparation of 3-hydroxy-4'-benzyloxyflavone A 10% solution of potassium hydroxide in water (15 ml) and a solution of hydrogen peroxide (100 vol., 2 ml) are added to a boiling solution of the chalcone described in a (3 mmol) in ethanol ~15 ml). After 15 minutes, the solution is poured into a mixture of ice and hydrochloric acid and the precipitate formed is filtered off. It is washed with water and recrystallized from an ethanol/acetone mixture (yield: 42%). M.p. =
176C.
Other 3-hydroxyflavones are prepared in the same way:
Table II
Yield M.p. (C) %
3-hydroxy-4'-benzyloxy-5-methoxy-flavone 30 165-166 3-hydroxy-4l-benzyloxy-6-methoxy-flavone 60 180-181 3-hydroxy-4'-benzyloxy`-7-methoxy-flavone 34 169 3-hydroxy-4'-benzyloxy-8-methoxy-flavone 38 203 3-hydroxy-4'-benzyloxy-6-chloroflavone 72 203-204 3-hydroxy-4'-benzyloxy-7-chloroflavone 62 ~250 3-hydroxy-4',6-dimethoxyflavone 65 182-183 3-hydroxy-4',8-dimethoxyflavone 34 212-214 3-hydroxy-4'-methoxy-6-benzyloxy-flavone 70 162-164 3-hydroxy-4'-methoxy-7-chloroflavone 55 190-191 ~284640 3-hydroxy-4',6-dichloroflavone 58 216-217 3-hydroxy-4',7-dichloroflavone 50 199-200 3-hydroxy-4'-benzyloxy-6-methylflavone 62 213 3-hydroxy-4'-benzyloxy-7-methylflavone 50 157-158 3-hydroxy-4'-benzyloxy-7-fluoroflavone 44 178-179 3-hydroxy-4'-benzyloxy-6-chloro-8-methylflavone 50 218-219 3-hydroxy-4'-chloro-7-methy,lflavone 61 197-198 c) Preparation of 3-methoxy-4'-benzyloxyflavone Potassium carbonate (3 mmol) and dimethyl sulphate (2 mmol) are added to an acetone solution of the 3-hydroxyflavone obtained in b (1 mmol). The mixture is heated under reflux for 12 hours. The solvent is evaporated off. Water is added until the precipitate has dissolved. The precipitate is filtered off and re-crystallized from ethanol (yield: 63~).
Other 3-methoxy-4'-benzyloxyflavones are pre-pared in the same way:
Table III
Yield Solvent M.p. (C) 3-methoxy-4'-benzyloxyflavone 63 EtOH 112 3,5-dimethoxy-4'-benzyloxy-flavone 72 MeOH 120-122 3,6-dimethoxy-4'-benzyloxy-flavone 60 MeOH 135-136 3,7-dimethoxy-4'-benzyloxy-flavone 72 MeOH 149-151 3,8-dimethoxy-4'-benzyloxy-flavone 60 MeOH/ 170-171 - acetone '3-methoxy-4'-benzyloxy-6-chloroflavone 92 MeOH 142-143 1~84~1D
3-methoxy-4'-benzyloxy-7-chloroflavone 70MeOH/ 131-132 acetone 3-methoxy-4'-benzyloxy-6-methylflavone 85 MeOH 133-134 3-methoxy-4'-benzyloxy-7-methylflavone 78MeOH/H20 123-124 3-methoxy-4'-benzyloxy-7-fluoroflavone 87 MeOH 132-133 3-methoxy-4'-benzyloxy-6- 92MeOH/ 126-127 chloro-8-methoxyflavone acetone 3,4'-dimethoxy-6-benzvloxyflavone 72 MeOH/ 117-118 acetone 3-methoxy-4',6-dichloroflavone88 MeOH/ 168-169 acetone 3-methoxy-4',7-dichloroflavone78 MeOH/ 171-172 acetone 3-methoxy-4'-chloro-7-methyl- 72 acetone/ 144-145 flavone MeOH
3,4',6-trimethoxyflavone 60MeOH 137-138 3,4',8-trimethoxyflavone 58EtOH 131-133 3,4'-dimethoxy-6-chloroflavone76 MeOH/ 135-136 acetone 3,4'-dimethoxy-7-chloroflavone80 MeOH/ 171-172 acetone d) Preparation of 4'-hydroxy-3-methoxyflavone 3-Methoxy-4-benzyloxyflavone (1 mmol) is heated under reflux in a mixture of concentrated hydrochloric acid (2 ml) and concentrated acetic acid (2 ml) for 3 hours. After dilution with water, the precipitate formed is filtered off and recrystallized from ethanol (yield:
72%). M.p. = 232-233C.
- Other 3-methoxyflavones are prepared in the same way:
~2846~L0 Table IV
Yield Solvent M.p. (C) %
3,5-dimethoxy-4'-hydroxyflavone81 EtOH./H20 206-208 3,6-dimethoxy-4'-hydroxyflavone82 EtOH 229-230 3,7-dimethoxy-4'-hydroxyflavone68 MeOH 224-226 3,8-dimethoxy-4'-hydroxyflavone72 MeOH 226-227 3-methoxy-4'-hydroxy-6-chloro-flavone 80EtOH 254-255 3-methoxy-4'-hydroxy-7-chloro- 85EtOH/ 266-267 10 flavone acetone 3-methoxy-4'-hydroxy-6-methyl-flavone 75MeOH 228-230 3-methoxy-4'-hydroxy-7-methyl-flavone 70MeOH 219-220 15 3-methoxy-4'-hydroxy-7-fluoro-flavone 69MeOH 228-229 3-methoxy-4'-hydroxy-6-chloro- 60MeOH/ 292-293 8-methylflavone acetone The compounds which are used in the present invention inhibit the reproduction of picornaviruses, including hepatitis A virus, rhabdoviruses and other viruses which cause human or animal diseases.
The results of an in vitro study of the antiviral activity of the compounds used in the present invention, towards certain picornavirusesj will be given below in Table V.
. The antiviral activity has been expressed as the viral strength reduction factor by the method known as EPTT (end point titration technique) (cf. Vanden Lerghe et al., Lloydia, 1978, 41, 463).
1~84~0 ___ ~O~ ê
_ ~ ~o ~o~o ~o o o ~o~o ~o o ~ ~ e ~ ~ 2 ~
o ~ ._ l .~
o o o ;~
~2a4640 Furthermore, the 50% lethal dose (LD50), the 90% and 99% effective doses (EDgo and EDg9) and the 90% and 99% therapeutic indices (TIgo and TIg9) were determined using the following methods:
a) Preparation of the compounds The compounds were prepared at a dose of 1 mg/ml in a maximum volume of 0.1 ml of dimethyl sulphoxide, the volume being made up to 12 ml by the addition of a maintenance medium M-2. The dilutions were made up with the maintenance medium M-2.
b) Determination of the antiviral activity by the method known as the "end point titration technique"
Monolayers of VER0 cells in microdishes were infected with 10-fold dilutions of the virus ~polio type I). After absorption of the virus onto the cells (60 minutes, 37C), the compounds ln the medium M-2 are added to the infected cultures. The dishes were incubated at 37C for a sufficient time to allow the cytopathogenic effect (CPE) to appear. The antiviral activity was determined on the basis of this effect.
The viral strength reduction factor is calculated for each dilution as the ratio of the dilution of the virus with no cytopathogenic effect to the dilution of the virus ~ compound with no cytopathogenic effect.
The 90% effective dose, EDgo, is the dose at which 90~ of the viruses are inhibited.
The 99% effective dose, EDg9, is the dose at which 99~ of the viruses are inhibited.
c) Determination of the lethal dose The LD50 is the concentration at which 50% of the growth of the normal cells is inhibited. This was determined using a suspension of 5 105 VER0 cells in 10 ml of E199 medium to which 6% of calf serum (CS) and gentamycin (20 micrograms/ml) have been added. The compounds were added to give final concentrations of 1~84~
200, 100, 75, S0, 25, 10, 5, 3, 2, 1, ~,1 an-1 0,01 micro~rams~ml~
d) Calculation of the therapeutic index The TI90 and TIg9 ar~ the value of the LD50 divided by EDgo and ED99 respectively.
The results are given in Table VI:
Ta~le VI
Compound LD50 ED90 TI 9D ~Dg g TIg9 3-methoxy-4'-hydroxyflavone 10 3 3.3 6 1.66 3,6-dimethoxy-4'-hydroxy-flavone 200 7 29 25 8 3-methoxv-4'-hydroxy-6-chloroflavone 100 2 50 6 17 3-methoxy-4~-hydroxy-6- 1 methylflavone 75 1 75 1 5 ¦15 15 3-methoxy-4',6-dihydroxy-flavone 3 0.5 6 2 1,.5 3,4'-dimethoxy-6-hydroxy-flavone 200 100 2 200 1 3,4',6-trimethoxyflavone 100 2 50 50 2 20 3-methoxy-4'-hydroxy-7- I !
chloroflavone 100 5 20 ' 7 14.3 3-methoxy-4'-hydroxy-7-methylflavone 25 0.5 50 2 l12.5 3-methoxy-4'-hydroxy-7-fluoroflavone 20 1 20 6 j3.2 3,7-dimethoxy-4'-hydroxy- l flavone 25 1 1 25 ¦ 5 ! 5 3-methoxy-4'-chloro-7- l methyIflavone 10 10 1 20 O.S
30 3,5-dimethoxy-4'-hydroxy-flavone 150 S ¦ 30 10 15 3,8-dimethoxy-4'-hydroxy-flavone 25 10 2.5 20 1.2 12846~0 3,4',6-trimethoxy-5,7-di-h-droxyflavone 5C l 50 lO 5 3,6-dimethoxy-4',5,7-tri-hydroxyflavone 20 0.5 40 1 20 3,6,7-trimethoxy-4',5-di-hydroxyflavone 100 0.5 200 5 20 3,3',4',6,7,8-hexamethoxy-5-hydroxyflavone 200 20 10 25 8 3,3',4',5,6,7,8-hepta-methoxyflavone 200 20 10 25 8 3,3',4',5,6,7-hexamethoxy-10 flavone 200 100 2 200 1 3-methoxy-4'-benzyloxyflavon~ 100 30 3.3 100 1 The therapeutic compositions according to the invention can therefore be used in both curative and preventive capacities.
The therapeutic compositions according to the invention can be administered topically, orally or parenterally to humans or animals.
They can be in the form of solid, semi-solid or liquid preparations. Examples which may be mentioned are tablets, gelatin capsules, suppositories, injectable solutions or suspensions, ointments, oil-based or water-based eye lotions, mouthwashes and nose and ear solutions, as well as delayed-action forms.
In these compositions, the active principle is generally mixed with one or more of the usual pharma-ceutically acceptable excipients which are well known to those skilled in the art.
~2B4640 The therapeutic compositions which can be administered topically can contain in particular from 0.1 to 5% by weight of active principle.
The therapeutic compositions which can be administered orally or parenterally can contain in par-ticular from 1% to 60% by weight of active principle.
The amount of active principle administered obviously depends on the patient being treated, the method of administration and the severity of the disease.
However, for oral or parenteral administration, it is possible to administer about 100 to 1000 mg -3 to 6 times per day. For topical administration, it is possible to administer from 0.1 to 100 micrograms/cml 3 to 6 times per day.
1284~
or 3) R1, R2, R3 and R4 are selected from the group com-prising a hydrogen atom, a hydroxy group and a C~-C4 . alkoxy group, three of these groups being other than hydrogen, R5 and Rg are selected from the group comprising a hydrogen atom, a hydroxy group and a C1-C4 alkoxy group, R6 and R8 are hydrogen atoms, and 10 R7 is a hydroxy, a cl-c4 a~oxy ~roU2 or ~ cos~lo~ group;
or 4) R3 and R4 are hydrogen atoms, R1 and R2 are selected from the group comprising a hydroxy group and a C1-C4 alkoxy group, R5, R6, R8 and R9 are selected from the group comprising a hydrogen atom, a hydroxy group and a C1-C4 alkoxy group, and R7 is a hydroxy , C~-C4 alkoxy or glycosyloxy group;
or 5) R~ and R4 are hydrogen atoms, R2 and R~ are selected from the group comprising a hydroxy group and a C1 -C4 alkoxy group, R5, R6, R8 and Rg are selected from the group comprising a hydrogen atom, a hydroxy group and a C~-C4 alkoxy group, and R7 is a hydroxy . C1-C4 alkoxy or glycosyloxy group;
or 6) R3 is a hydrogen atom, Rl, R2 and R4 are selected from the group comprising a hydrogen atom, a hydroxy group and a Cl-C4 alkoxy group, two of these groups being other than hydrogen, R5, R6, R8 and Rg are selected from the group comprising a hydrogen atom, a hydroxy group and a Cl-C4 alkoxy group, and R7 is a hydroxy , Cl-C4 alkoxy or glycosyloxy group;
or 7) Rl, R2, R3 and R4 are selected from the group com-prising a hydrogen atom, a hydroxy group and a C1-C4 alkoxy group, at least three of these groups being a hydrogen atom, R5, R6, R8 and Rg are selected from the group com-prising a hydrogen atom, a hydroxy group and a Cl-C4 alkoxy group, and R7 is a hydroxy , C1-C4 alkoxy or glycosyloxy 10 qroup, ora pharmaceutically acceptable salt thereof.
In the above definition, the expression "a halogen atom" denotes a chlorine, bromine, iodine or fluorine atom.
Pharmaceutically acceptable salts are the addition salts which the compounds form with pharma-ceutically acceptable acids, as well as the salts which the compounds containing an acid group (COOH) form with pharmaceutically acceptable bases.
The expression "addition salts with pharma-ceutically acceptable acids" denotes salts which givethe biological properties of the free bases without having any undesirable effects. In particular, these salts can be those formed with mineral acids such as hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid and phosphoric acid, with metal salts con-taining acid hydrogens, such as disodium orthophosphate and monopotassium sulphate, and with organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, oxalic acid, fumaric acid, lactic acid, succinic acid, tartaric acid and pamoic acid.
Likewise, the expression "salts with pharma-ceutically acceptable bases" denotes salts which do not modify the biological properties of the free acids. In particular, these salts can be those formed with in-organic bases such as sodium hydroxide, potassium ~284~
-- 5 ~
hydroxide, lithium hydroxide, calcium hydroxide andmagnesium hydroxide, or with organic baseS such as glucamine, N-methylglucamine, N~N-dimethylglucamine~
ethanolamine, diethanolamine, morpholine, N-methyl-morpholine and tris(hydroxymethyl)methylamine.
To the knowledge of the Applicant Company, thecompounds of the formula I belonging to the class defined under 1) are novel compounds.
The compounds belonging to the classes defined under 2) to 7) are products of natural origin or derivatives of products of natural origin.
The Applicant Company has also found that 3,3', 4',5,6,7,8-heptamethoxyflavone has an antiviral activity.
The compound was described in US-A-3 867 541 as havina an aggregation-inhibiting activity, with no suggestion of a viral activity. The invention also relates to the use of this compound for the manu-facture of a pharmaceutical composition for treating viral diseases.
In general terms, the 3-alkoxyflavones used in the present invention can be obtained by one of the following processes:
1) Alkylation of 3-hydroxyflavones according to the following scheme:
~3 ~ ~ 7 III
l RZ
~284640 3 ~ J ~ ~ 37 in which Z is a nucleus-repelling group.
Methyl sulphate, methyl iodide or diazomethane may be mentioned as examples of methylating agents.
2) Synthesis by the Allan-Robinson method (J. Chem. Soc.
125, 2192, 1924), in which o-hydroxyaryl ketones are condensed with aromatic acid anhydrides according to the following scheme:
A2~CO-CH2_oQ ~ ~ ~ >
X XI
2 ~
In this method, any hydroxy groups present can be protected, if necessary, and deprotected after the reaction.
~Z846~0 As a variant, using the same type of reaction, it is possible to prepare a 3-hydroxyflavone and then carry out an alkylation as described in 1.
3) The Algar-Flynn-Oyamada oxidation metho~ (J. Algar, J.P. Flynn, Proc. Roy. Irish Acad. 423, 1, 1934; B.
Oyamada, J. Chem. Soc. Japan 55, 1256, 1934), which consists in oxidizing chalcones with hydrogen peroxide in an alkaline medium, this being followed by an alkylation reaction as described in 1, according to the following scheme:
~3 ~ IIH ~R~ II
Rl I
j alkylat~on 3~ ~ 7 ~za4~o In this method, any hydroxy~ groups present can be protected and deprotected at the end.
4) The nuclear reduction of an ester, for example according to the following reaction scheme:
HO = R7 XIV
Rl O
l~ ClY
R4 R ~ R6 ~ `1~ )--2 ~ OR I ~ R
1H2 /Raney Ni ~2 ~ ; R7 XVI
1;2B46~0 Y being, for example, a p-toluenesulphonyl radical.
5) Nuclear oxidation, for example with persulphate, according to the following scheme:
~3 = ~7 Rl O
oxidation ~ /
~3 ~ ; ~ ~7 Rl O
A number of 3-alkoxyflavones which can be used in the present invention are present in plants and can be obtained by extraction.
The extraction method is as follows:
The leaves of the plants are macerated with 80~ ethanol at room temperature for 2 hours, with stirring. After maceration, the leaves are filtered off and the filtra-tion residue is percolated with the same solvent. The filtrate and the percolation liquid are combined and concentrated in vacuo (at a temperature below 40C) to give a thick extract. The extract is partitioned between 90% methanol and hexane (or a 40-60 petroleum ether).
The methanol phase is separated off and evaporated to dryness. The residue obtained is partitioned between l2s464al water (pH 5) and ethyl acetate. The etHyl acetate phase is separated off and evaporated to dryness. The residue obtained is subjected to countercurrent chroma-tography, dropwise, using a chloroform/water/methanol mixture (7:8:13) as the eluent by the descending tech-nique. The effluent is monitored at 355 nm and by thin layer chro~atography or by high performance liquid chromatography, and the antiviral activity of the fractions is tested. The fractions with antiviral activity are evaporated and then chromatographed on Sephadex~LH 20 using methanol as the eluent, and the eluate is monitored as before. The active fractions are chromatographed on a column of silica gel impregna-ted with 5% of water, a hexane/ethyl acetate/acetic acid mixture (5:3:1) being used as the developer in accordance with the "dry column" technique. This gives the pure active 3-alkoxyflavones.
The examples which follow illustrate the prepara-tion of the compounds of the formula I.
Example: Preparation of 4'-hydroxy-3-methoxyflavone (Algar-Flynn-Oyamada method) a) Preparation of 2'-hydroxy-4-benzyloxychalcone A solution of 2-hydroxyacetophenone (25 mmol) and benzyloxybenzaldehyde (25 mmol) in 25 ml of ethanol is cooled with ice. A 50% solution of potassium hydroxide (25 ml) is added slowly and the mixture is stirred for 4 days at room temperature. The solution is again cooled with ice and acidified with dilute hydrochloric acid. The precipitate is filtered off, washed with water and recrystallized from ethanol (yield: 59%). M.p. = 112-113C.
Other chalcones are prepared in the same way:
* 7`~ /c ~
l;~B4~
Table I
Yield M.p. (C) %
2'-hydroxy-4-benzyloxy-6'-methoxy-chalcone S0 111-112 2'-hydroxy-4-benzyloxy-5'-methoxy-chalcone 50 142-143 2'-hydroxy-4-benzyloxy-4'-methoxy-chalcone 35 123-124 2'-hydroxy-3'-methoxy-4-benzyloxy-chalcone ~ 45 152-153 2'-hydroxy-4,5'-dibenzyloxychalcone 59 121-122 2'-hydroxy-4,4'-dibenzyloxychalcone 55 134-136 2'-hydroxy-4-benzyloxy-5'-chloro-chalcone 88 100-102 2'-hydroxy-4-benzyloxy-4'-chloro-chalcone 40 140-141 2'-hydroxy-4,6'-dimethoxychalcone 58 98-100 2'-hydroxy-4,5'-dimethoxychalcone 78 63-64 2'-hydroxy-3',4-dimethoxychalcone 74 118 2'-hydroxy-4-methoxy-6'-benzyloxy-chalcone 55 75-76 2'-hydroxy-4-methoxy-5'-benzyloxy-chalcone 72 89-92 2'-hydroxy-4-methoxy-5'-chlorochalcone40 191-192 2'-hydroxy-4-methoxy-4'-chlorochalcone68 128-129 2'-hydroxy-4-chloro-6'-methoxychalcone50 116-111 2'-hydroxy-4,5'-dichlorochalcone 60 188-189 2'-hydroxy-4,4'-dichlorochalcone 80 150-151 2'-hydroxy-4-benzyloxy-5'-methyl-chalcone 53 139 2'-hydroxy-4-benzyloxy-4'-methyl-chalcone 52 144-145 2'-hydroxy-4-benzyloxy-4'-fluoro-chalcone 75 119-120 lZ846410 2'-hydroxy-3'-methyl-4-benzyloxy-5'-chlorochalcone 85 153-154 2'-hydroxy-4-chloro-4'-methylchalcone 55 145 , b) Preparation of 3-hydroxy-4'-benzyloxyflavone A 10% solution of potassium hydroxide in water (15 ml) and a solution of hydrogen peroxide (100 vol., 2 ml) are added to a boiling solution of the chalcone described in a (3 mmol) in ethanol ~15 ml). After 15 minutes, the solution is poured into a mixture of ice and hydrochloric acid and the precipitate formed is filtered off. It is washed with water and recrystallized from an ethanol/acetone mixture (yield: 42%). M.p. =
176C.
Other 3-hydroxyflavones are prepared in the same way:
Table II
Yield M.p. (C) %
3-hydroxy-4'-benzyloxy-5-methoxy-flavone 30 165-166 3-hydroxy-4l-benzyloxy-6-methoxy-flavone 60 180-181 3-hydroxy-4'-benzyloxy`-7-methoxy-flavone 34 169 3-hydroxy-4'-benzyloxy-8-methoxy-flavone 38 203 3-hydroxy-4'-benzyloxy-6-chloroflavone 72 203-204 3-hydroxy-4'-benzyloxy-7-chloroflavone 62 ~250 3-hydroxy-4',6-dimethoxyflavone 65 182-183 3-hydroxy-4',8-dimethoxyflavone 34 212-214 3-hydroxy-4'-methoxy-6-benzyloxy-flavone 70 162-164 3-hydroxy-4'-methoxy-7-chloroflavone 55 190-191 ~284640 3-hydroxy-4',6-dichloroflavone 58 216-217 3-hydroxy-4',7-dichloroflavone 50 199-200 3-hydroxy-4'-benzyloxy-6-methylflavone 62 213 3-hydroxy-4'-benzyloxy-7-methylflavone 50 157-158 3-hydroxy-4'-benzyloxy-7-fluoroflavone 44 178-179 3-hydroxy-4'-benzyloxy-6-chloro-8-methylflavone 50 218-219 3-hydroxy-4'-chloro-7-methy,lflavone 61 197-198 c) Preparation of 3-methoxy-4'-benzyloxyflavone Potassium carbonate (3 mmol) and dimethyl sulphate (2 mmol) are added to an acetone solution of the 3-hydroxyflavone obtained in b (1 mmol). The mixture is heated under reflux for 12 hours. The solvent is evaporated off. Water is added until the precipitate has dissolved. The precipitate is filtered off and re-crystallized from ethanol (yield: 63~).
Other 3-methoxy-4'-benzyloxyflavones are pre-pared in the same way:
Table III
Yield Solvent M.p. (C) 3-methoxy-4'-benzyloxyflavone 63 EtOH 112 3,5-dimethoxy-4'-benzyloxy-flavone 72 MeOH 120-122 3,6-dimethoxy-4'-benzyloxy-flavone 60 MeOH 135-136 3,7-dimethoxy-4'-benzyloxy-flavone 72 MeOH 149-151 3,8-dimethoxy-4'-benzyloxy-flavone 60 MeOH/ 170-171 - acetone '3-methoxy-4'-benzyloxy-6-chloroflavone 92 MeOH 142-143 1~84~1D
3-methoxy-4'-benzyloxy-7-chloroflavone 70MeOH/ 131-132 acetone 3-methoxy-4'-benzyloxy-6-methylflavone 85 MeOH 133-134 3-methoxy-4'-benzyloxy-7-methylflavone 78MeOH/H20 123-124 3-methoxy-4'-benzyloxy-7-fluoroflavone 87 MeOH 132-133 3-methoxy-4'-benzyloxy-6- 92MeOH/ 126-127 chloro-8-methoxyflavone acetone 3,4'-dimethoxy-6-benzvloxyflavone 72 MeOH/ 117-118 acetone 3-methoxy-4',6-dichloroflavone88 MeOH/ 168-169 acetone 3-methoxy-4',7-dichloroflavone78 MeOH/ 171-172 acetone 3-methoxy-4'-chloro-7-methyl- 72 acetone/ 144-145 flavone MeOH
3,4',6-trimethoxyflavone 60MeOH 137-138 3,4',8-trimethoxyflavone 58EtOH 131-133 3,4'-dimethoxy-6-chloroflavone76 MeOH/ 135-136 acetone 3,4'-dimethoxy-7-chloroflavone80 MeOH/ 171-172 acetone d) Preparation of 4'-hydroxy-3-methoxyflavone 3-Methoxy-4-benzyloxyflavone (1 mmol) is heated under reflux in a mixture of concentrated hydrochloric acid (2 ml) and concentrated acetic acid (2 ml) for 3 hours. After dilution with water, the precipitate formed is filtered off and recrystallized from ethanol (yield:
72%). M.p. = 232-233C.
- Other 3-methoxyflavones are prepared in the same way:
~2846~L0 Table IV
Yield Solvent M.p. (C) %
3,5-dimethoxy-4'-hydroxyflavone81 EtOH./H20 206-208 3,6-dimethoxy-4'-hydroxyflavone82 EtOH 229-230 3,7-dimethoxy-4'-hydroxyflavone68 MeOH 224-226 3,8-dimethoxy-4'-hydroxyflavone72 MeOH 226-227 3-methoxy-4'-hydroxy-6-chloro-flavone 80EtOH 254-255 3-methoxy-4'-hydroxy-7-chloro- 85EtOH/ 266-267 10 flavone acetone 3-methoxy-4'-hydroxy-6-methyl-flavone 75MeOH 228-230 3-methoxy-4'-hydroxy-7-methyl-flavone 70MeOH 219-220 15 3-methoxy-4'-hydroxy-7-fluoro-flavone 69MeOH 228-229 3-methoxy-4'-hydroxy-6-chloro- 60MeOH/ 292-293 8-methylflavone acetone The compounds which are used in the present invention inhibit the reproduction of picornaviruses, including hepatitis A virus, rhabdoviruses and other viruses which cause human or animal diseases.
The results of an in vitro study of the antiviral activity of the compounds used in the present invention, towards certain picornavirusesj will be given below in Table V.
. The antiviral activity has been expressed as the viral strength reduction factor by the method known as EPTT (end point titration technique) (cf. Vanden Lerghe et al., Lloydia, 1978, 41, 463).
1~84~0 ___ ~O~ ê
_ ~ ~o ~o~o ~o o o ~o~o ~o o ~ ~ e ~ ~ 2 ~
o ~ ._ l .~
o o o ;~
~2a4640 Furthermore, the 50% lethal dose (LD50), the 90% and 99% effective doses (EDgo and EDg9) and the 90% and 99% therapeutic indices (TIgo and TIg9) were determined using the following methods:
a) Preparation of the compounds The compounds were prepared at a dose of 1 mg/ml in a maximum volume of 0.1 ml of dimethyl sulphoxide, the volume being made up to 12 ml by the addition of a maintenance medium M-2. The dilutions were made up with the maintenance medium M-2.
b) Determination of the antiviral activity by the method known as the "end point titration technique"
Monolayers of VER0 cells in microdishes were infected with 10-fold dilutions of the virus ~polio type I). After absorption of the virus onto the cells (60 minutes, 37C), the compounds ln the medium M-2 are added to the infected cultures. The dishes were incubated at 37C for a sufficient time to allow the cytopathogenic effect (CPE) to appear. The antiviral activity was determined on the basis of this effect.
The viral strength reduction factor is calculated for each dilution as the ratio of the dilution of the virus with no cytopathogenic effect to the dilution of the virus ~ compound with no cytopathogenic effect.
The 90% effective dose, EDgo, is the dose at which 90~ of the viruses are inhibited.
The 99% effective dose, EDg9, is the dose at which 99~ of the viruses are inhibited.
c) Determination of the lethal dose The LD50 is the concentration at which 50% of the growth of the normal cells is inhibited. This was determined using a suspension of 5 105 VER0 cells in 10 ml of E199 medium to which 6% of calf serum (CS) and gentamycin (20 micrograms/ml) have been added. The compounds were added to give final concentrations of 1~84~
200, 100, 75, S0, 25, 10, 5, 3, 2, 1, ~,1 an-1 0,01 micro~rams~ml~
d) Calculation of the therapeutic index The TI90 and TIg9 ar~ the value of the LD50 divided by EDgo and ED99 respectively.
The results are given in Table VI:
Ta~le VI
Compound LD50 ED90 TI 9D ~Dg g TIg9 3-methoxy-4'-hydroxyflavone 10 3 3.3 6 1.66 3,6-dimethoxy-4'-hydroxy-flavone 200 7 29 25 8 3-methoxv-4'-hydroxy-6-chloroflavone 100 2 50 6 17 3-methoxy-4~-hydroxy-6- 1 methylflavone 75 1 75 1 5 ¦15 15 3-methoxy-4',6-dihydroxy-flavone 3 0.5 6 2 1,.5 3,4'-dimethoxy-6-hydroxy-flavone 200 100 2 200 1 3,4',6-trimethoxyflavone 100 2 50 50 2 20 3-methoxy-4'-hydroxy-7- I !
chloroflavone 100 5 20 ' 7 14.3 3-methoxy-4'-hydroxy-7-methylflavone 25 0.5 50 2 l12.5 3-methoxy-4'-hydroxy-7-fluoroflavone 20 1 20 6 j3.2 3,7-dimethoxy-4'-hydroxy- l flavone 25 1 1 25 ¦ 5 ! 5 3-methoxy-4'-chloro-7- l methyIflavone 10 10 1 20 O.S
30 3,5-dimethoxy-4'-hydroxy-flavone 150 S ¦ 30 10 15 3,8-dimethoxy-4'-hydroxy-flavone 25 10 2.5 20 1.2 12846~0 3,4',6-trimethoxy-5,7-di-h-droxyflavone 5C l 50 lO 5 3,6-dimethoxy-4',5,7-tri-hydroxyflavone 20 0.5 40 1 20 3,6,7-trimethoxy-4',5-di-hydroxyflavone 100 0.5 200 5 20 3,3',4',6,7,8-hexamethoxy-5-hydroxyflavone 200 20 10 25 8 3,3',4',5,6,7,8-hepta-methoxyflavone 200 20 10 25 8 3,3',4',5,6,7-hexamethoxy-10 flavone 200 100 2 200 1 3-methoxy-4'-benzyloxyflavon~ 100 30 3.3 100 1 The therapeutic compositions according to the invention can therefore be used in both curative and preventive capacities.
The therapeutic compositions according to the invention can be administered topically, orally or parenterally to humans or animals.
They can be in the form of solid, semi-solid or liquid preparations. Examples which may be mentioned are tablets, gelatin capsules, suppositories, injectable solutions or suspensions, ointments, oil-based or water-based eye lotions, mouthwashes and nose and ear solutions, as well as delayed-action forms.
In these compositions, the active principle is generally mixed with one or more of the usual pharma-ceutically acceptable excipients which are well known to those skilled in the art.
~2B4640 The therapeutic compositions which can be administered topically can contain in particular from 0.1 to 5% by weight of active principle.
The therapeutic compositions which can be administered orally or parenterally can contain in par-ticular from 1% to 60% by weight of active principle.
The amount of active principle administered obviously depends on the patient being treated, the method of administration and the severity of the disease.
However, for oral or parenteral administration, it is possible to administer about 100 to 1000 mg -3 to 6 times per day. For topical administration, it is possible to administer from 0.1 to 100 micrograms/cml 3 to 6 times per day.
Claims (10)
1. A therapeutic composition having an antiviral activity containing an effective amount of a compound selected from the compounds of the general formula in which :
R is C1 - C4 alkyl and l) R1, R2, R3 and R4 are selected from the group consisting of hydrogen, halogen, nitro, cyano, trifluoromethyl, C1 - C4 alkyl,C1 - C4 alkoxy,benzyloxy, methylenedioxy,C1 - C4 alka-noyl,(C1 - C4 alkoxy)carbonyloxy, amino, (C1-C4alkyl)amino, di(C1-C4 alkyl)amino,hydroxy, (C1-4 alkanoyl)oxy, glycosyloxy,car-boxy and (C1-C4 alkoxy)carbonyl, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, halogen, hydroxy, C1-C4 alkoxy, benzyloxy and C1-C4 alkyl, at least one of the groups R1, R2, R3, R4, R5, R6, R8 and R9 being other than hydrogen, hydroxy or C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy and glycosyloxy ;
R is C1 - C4 alkyl and l) R1, R2, R3 and R4 are selected from the group consisting of hydrogen, halogen, nitro, cyano, trifluoromethyl, C1 - C4 alkyl,C1 - C4 alkoxy,benzyloxy, methylenedioxy,C1 - C4 alka-noyl,(C1 - C4 alkoxy)carbonyloxy, amino, (C1-C4alkyl)amino, di(C1-C4 alkyl)amino,hydroxy, (C1-4 alkanoyl)oxy, glycosyloxy,car-boxy and (C1-C4 alkoxy)carbonyl, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, halogen, hydroxy, C1-C4 alkoxy, benzyloxy and C1-C4 alkyl, at least one of the groups R1, R2, R3, R4, R5, R6, R8 and R9 being other than hydrogen, hydroxy or C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy and glycosyloxy ;
2) R1, R2, R3 and R4 are selected from the group consist-ing of hydroxy. and C1-C4 alkoxy, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group cons-isting of hydroxy, C1-C4 alkoxy and glycosyloxy, with the exclusion of 3,3', 4',5,6,7,8-heptamethoxyflavone; or
3) R1, R2, R3 and R4 are selected from the group consist-ing of hydrogen, hydroxy and C1-C4 alkoxy, three of these groups being other than hydrogen, R5 and R9 are selected from the group consisting of hydro-gen, hydroxy and C1-C4 alkoxy, R6 and R8 are hydrogen and R7 is selected from the group consisting of hydroxy , C1-C4 alkoxy and glycosyloxy;
or
or
4) R3 and R4 are hydrogen, R1 and R2 are selected from the group consisting of hydroxy and C1-C4 alkoxy, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy, C1-C4 alkoxy and glycosyloxy, or
5) R1 and R4 are hydrogen, R2 and R3 are selected from the group consisting of hydroxy and C1-C4 alkoxy, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy, C1-C4 alkoxy and glycosyloxy;
or
or
6) R3 is hydrogen, R1, R2 and R4 are selected from the group consisting of hydro-gen, hydroxy and C16C4 alkoxy, two of these groups being other than hydrogen, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy, C1-C4 alkoxy and glycosyloxy, or
7) R1, R2, R3 and R4 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, at least three of these groups being hydrogen, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy, C1-C4 alkoxy and glycosyloxy, and a pharmaceutically acceptable salt thereof, and a therapeutically acceptable excipient.
2. A composition as claimed in claim 1, containing an effective amount of a compound of the formula:
in which:
R is C1-C4 alkyl, R1, R2 , R3 and R4 are selected from the group consisting of hydrogen, halogen,nitro, cyano, trifluoromethyl, C1-C4 alkyl, C1-C4 alkoxy, benzyloxy, methyleredioxy, C1-C4 alkanoyl, (C1-C4 alkoxy)carbonyloxy, amino, (C1-C4 alkyl)amino, di(C1-C4 alkyl)amino, (C1-C4 alkanoyl)amino, hydroxy (C1-C4 al-kanoyl)oxy, glycosyloxy, carboxy and (C1-C4 alkoxy)carbonyl, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, halogen, hydroxy, C1-C4 alkoxy, benzyloxy and C1-C4 alkyl, al least one of the groups R1, R2, R3, R4, R5, R6, R8 and R9 being other than hydrogen, hydroxy or C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy and glycosyloxy.
3. A composition as claimed in claim 1 containing an effective amount of a compound of the formula:
in which:
R is C1-C4 alkyl, R1, R2, R3 and R4 are selected from the group consisting of hydroxy and C1-C4 alkoxy, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy, C1-C4 alkoxy,and glycosyloxy, with the exclusion of 3,3', 4', 5, 6,7 8-heptamethoxy-flavone.
4. A composition as claimed in claim 1, containing an effective amount of a compound of the formula:
in which R is C1-C4 alkyl, R1,R2; R3 and R4 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, three of these groups being other than hydrogen, R5 and R9 are selected from the group consisting of hydro-gen, hydroxy and C1-C4 alkoxy, R6 and R8 are hydrogen, and R7 is selected from the group consisting of hydroxy and glycosyloxy.
5. A composition as claimed in claim 1, containing an effective amount of a compound of the formula:
in which:
R is C1-C4 alkyl, R3 and R4 are hydrogen, R1 and R2 are selected from the group consisting of hydroxy and C1-C4 alkoxy R5, R6 R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy, C1-C4 alkoxy and glycosyloxy.
6. A composition as claimed in claim 1, containing an effective amount of a compound of the formula:
in which:
R is C1-C4alkyl, R1 and R4 are hydrogen, R2 and R3 are selected from the group consisting of hydroxy and C1-C4 alkoxy, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy, C1-C4 alkoxy and glycosyloxy.
7. A composition as claimed in claim 1, containing an effective amount of a compound of the formula:
in which:
R is C1-C4 alkyl, R3 is hydrogen, R1, R2 and R4 are selected from the group consisting of hydro-gen, hydroxy and C1-C4 alkoxy, two of these groups being other than hydrogen, R5 R6, R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy, C1-C4 alkoxy and glycosyloxy.
2. A composition as claimed in claim 1, containing an effective amount of a compound of the formula:
in which:
R is C1-C4 alkyl, R1, R2 , R3 and R4 are selected from the group consisting of hydrogen, halogen,nitro, cyano, trifluoromethyl, C1-C4 alkyl, C1-C4 alkoxy, benzyloxy, methyleredioxy, C1-C4 alkanoyl, (C1-C4 alkoxy)carbonyloxy, amino, (C1-C4 alkyl)amino, di(C1-C4 alkyl)amino, (C1-C4 alkanoyl)amino, hydroxy (C1-C4 al-kanoyl)oxy, glycosyloxy, carboxy and (C1-C4 alkoxy)carbonyl, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, halogen, hydroxy, C1-C4 alkoxy, benzyloxy and C1-C4 alkyl, al least one of the groups R1, R2, R3, R4, R5, R6, R8 and R9 being other than hydrogen, hydroxy or C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy and glycosyloxy.
3. A composition as claimed in claim 1 containing an effective amount of a compound of the formula:
in which:
R is C1-C4 alkyl, R1, R2, R3 and R4 are selected from the group consisting of hydroxy and C1-C4 alkoxy, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy, C1-C4 alkoxy,and glycosyloxy, with the exclusion of 3,3', 4', 5, 6,7 8-heptamethoxy-flavone.
4. A composition as claimed in claim 1, containing an effective amount of a compound of the formula:
in which R is C1-C4 alkyl, R1,R2; R3 and R4 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, three of these groups being other than hydrogen, R5 and R9 are selected from the group consisting of hydro-gen, hydroxy and C1-C4 alkoxy, R6 and R8 are hydrogen, and R7 is selected from the group consisting of hydroxy and glycosyloxy.
5. A composition as claimed in claim 1, containing an effective amount of a compound of the formula:
in which:
R is C1-C4 alkyl, R3 and R4 are hydrogen, R1 and R2 are selected from the group consisting of hydroxy and C1-C4 alkoxy R5, R6 R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy, C1-C4 alkoxy and glycosyloxy.
6. A composition as claimed in claim 1, containing an effective amount of a compound of the formula:
in which:
R is C1-C4alkyl, R1 and R4 are hydrogen, R2 and R3 are selected from the group consisting of hydroxy and C1-C4 alkoxy, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy, C1-C4 alkoxy and glycosyloxy.
7. A composition as claimed in claim 1, containing an effective amount of a compound of the formula:
in which:
R is C1-C4 alkyl, R3 is hydrogen, R1, R2 and R4 are selected from the group consisting of hydro-gen, hydroxy and C1-C4 alkoxy, two of these groups being other than hydrogen, R5 R6, R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy, C1-C4 alkoxy and glycosyloxy.
8. A composition as claimed in claim 1, containing an effective amount of a compound of the formula:
in which:
R is C1-C4 alkyl R1, R2, R3 and R4 are selected from the group consisting of hydrogen. hydroxy and C1-C4 alkoxy, at least three of these groups being hydrogen, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy, C1-C4 alkoxy and glycosyloxy.
in which:
R is C1-C4 alkyl R1, R2, R3 and R4 are selected from the group consisting of hydrogen. hydroxy and C1-C4 alkoxy, at least three of these groups being hydrogen, R5, R6, R8 and R9 are selected from the group consisting of hydrogen, hydroxy and C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy, C1-C4 alkoxy and glycosyloxy.
9. Use of 3,3',4',5,6,7,8-heptamethoxyflavone for the manufacture of a pharmaceutical composition for treating viral diseases.
10. A co~pound selected from the compounds of the for-mula:
in which R is C1-C4 alkyl, R1, R2 , R3 and R4 are selected from the group consisting of hydrogen, halogen, nitro, cyano, trifluoromethyl, C1-C4 alkyl, C1-C4 alkoxy, benzyloxy, methylenedioxy, C1-C4 alkanoyl, (C1-C4 alkoxy)carbonyloxy, amino, (C1-C4 alkyl)amino, di(C1-C4 alkyl)amino, (C1-C4 alkanoyl)amino, hydroxy, (C1-C4alkanoyl) oxy, glycosyloxy, carboxy and (C1-C4 alkoxy)carbonyl), R5, R6, R8 and R9 are selected from the group consisting of hydrogen, halogen, hydroxy, C1-C4 alkoxy, benzyloxy and C1-C4 alkyl, at least one of the groups R1, R2, R3, R4, R5, R6, R8 and R9 being other than hydrogen, hydroxy or C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy and glycosyloxy, and their pharmaceutically acceptable salts.
in which R is C1-C4 alkyl, R1, R2 , R3 and R4 are selected from the group consisting of hydrogen, halogen, nitro, cyano, trifluoromethyl, C1-C4 alkyl, C1-C4 alkoxy, benzyloxy, methylenedioxy, C1-C4 alkanoyl, (C1-C4 alkoxy)carbonyloxy, amino, (C1-C4 alkyl)amino, di(C1-C4 alkyl)amino, (C1-C4 alkanoyl)amino, hydroxy, (C1-C4alkanoyl) oxy, glycosyloxy, carboxy and (C1-C4 alkoxy)carbonyl), R5, R6, R8 and R9 are selected from the group consisting of hydrogen, halogen, hydroxy, C1-C4 alkoxy, benzyloxy and C1-C4 alkyl, at least one of the groups R1, R2, R3, R4, R5, R6, R8 and R9 being other than hydrogen, hydroxy or C1-C4 alkoxy, and R7 is selected from the group consisting of hydroxy and glycosyloxy, and their pharmaceutically acceptable salts.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8600644 | 1986-01-17 | ||
FR8600644A FR2593066B1 (en) | 1986-01-17 | 1986-01-17 | THERAPEUTIC COMPOSITIONS BASED ON 3-ALKOXYFLAVON DERIVATIVES AND NEW 3-ALKOXYFLAVON DERIVATIVES. |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1284640C true CA1284640C (en) | 1991-06-04 |
Family
ID=9331224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000527372A Expired - Lifetime CA1284640C (en) | 1986-01-17 | 1987-01-15 | Therapeutic compositions based on 3-alkoxyflavone derivatives, and novel 3-alkoxyflavone derivatives |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0233105B1 (en) |
JP (1) | JPS62223179A (en) |
AT (1) | ATE59777T1 (en) |
CA (1) | CA1284640C (en) |
DE (1) | DE3767175D1 (en) |
DK (1) | DK24687A (en) |
FR (1) | FR2593066B1 (en) |
PT (1) | PT84130B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5539112A (en) * | 1992-02-14 | 1996-07-23 | Kyowa Hakko Kogyo Co., Ltd. | 5-aminoflavone derivatives |
IL118657A0 (en) * | 1996-06-14 | 1996-10-16 | Arad Dorit | Inhibitors for picornavirus proteases |
WO1998027080A1 (en) * | 1996-12-19 | 1998-06-25 | Agrevo Uk Limited | Chromones useful as fungicides |
IL122591A0 (en) | 1997-12-14 | 1998-06-15 | Arad Dorit | Pharmaceutical compositions comprising cystein protease inhibitors |
CN1837202B (en) * | 2006-04-25 | 2010-08-18 | 中国人民解放军第二军医大学 | Flavonols with blood-fat-lowering effect |
US20200079750A1 (en) * | 2017-04-21 | 2020-03-12 | Yuuzo Tsuchida | Compound or salt thereof, antiviral agent, and pharmaceutical composition |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3541M (en) * | 1964-05-12 | 1965-09-13 | Laroche Navarron Lab | Drug has natriuretic properties based on a new flavone. |
GB1139041A (en) * | 1966-05-25 | 1969-01-08 | Beecham Group Ltd | Chlorflavonin |
US3661890A (en) * | 1970-03-10 | 1972-05-09 | Us Agriculture | Preparation of quercetin derivatives |
US3867541A (en) * | 1972-05-03 | 1975-02-18 | Ralph C Robbins | Compositions and methods for disaggregating blood cells |
FR2187320A1 (en) * | 1972-06-09 | 1974-01-18 | Cortial | Flavoured extracts of birch - with cytolytic activity |
GB1461777A (en) * | 1973-06-08 | 1977-01-19 | Fisons Ltd | 2-phenyl-4-oxo-4h-1-benzopyran derivatives |
NZ193316A (en) * | 1979-04-10 | 1984-07-31 | Hoffmann La Roche | 3-alkoxyflavone derivatives and pharmaceutical compositions |
JPS5899414A (en) * | 1981-12-10 | 1983-06-13 | Jun Okuda | Inhibitor of aldose reductase |
-
1986
- 1986-01-17 FR FR8600644A patent/FR2593066B1/en not_active Expired
-
1987
- 1987-01-15 CA CA000527372A patent/CA1284640C/en not_active Expired - Lifetime
- 1987-01-16 DE DE8787400107T patent/DE3767175D1/en not_active Expired - Lifetime
- 1987-01-16 EP EP87400107A patent/EP0233105B1/en not_active Expired - Lifetime
- 1987-01-16 PT PT84130A patent/PT84130B/en not_active IP Right Cessation
- 1987-01-16 AT AT87400107T patent/ATE59777T1/en not_active IP Right Cessation
- 1987-01-16 JP JP62007955A patent/JPS62223179A/en active Pending
- 1987-01-16 DK DK024687A patent/DK24687A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DK24687D0 (en) | 1987-01-16 |
EP0233105A1 (en) | 1987-08-19 |
DE3767175D1 (en) | 1991-02-14 |
EP0233105B1 (en) | 1991-01-09 |
ATE59777T1 (en) | 1991-01-15 |
JPS62223179A (en) | 1987-10-01 |
FR2593066A1 (en) | 1987-07-24 |
PT84130B (en) | 1989-02-28 |
DK24687A (en) | 1987-07-18 |
FR2593066B1 (en) | 1989-06-30 |
PT84130A (en) | 1987-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Anti-AIDS agents—XXVI. Structure-activity correlations of gomisin-G-related anti-HIV lignans from Kadsura interior and of related synthetic analogues | |
WO2004037193A2 (en) | Chromones and chromone derivatives and uses thereof | |
WO2008014722A1 (en) | Prenyl flavonoids,their preparation and use | |
Mateeva et al. | Synthesis of novel flavonoid derivatives as potential HIV‐Integrase inhibitors | |
SU1072805A3 (en) | Process for preparing derivatives of flavan or their salts | |
CA1284640C (en) | Therapeutic compositions based on 3-alkoxyflavone derivatives, and novel 3-alkoxyflavone derivatives | |
US4737517A (en) | Coumarin derivatives, pharmaceutical compositions containing the same, and the use thereof in the treatment of cancer | |
US4970301A (en) | 2-(piperazinyl)-2-oxoethylene-substituted flavonoid compounds | |
CN107652261B (en) | Calycosin derivative and synthetic method thereof | |
CN1546451A (en) | Hydroxyanthraquinone derivatives and their application in preparation of anticancer medicines | |
Wang et al. | Anticancer drugs II Synthesis and biological evaluation of spin labeled derivatives of podophyllotoxin | |
US5750577A (en) | Chromotropic acid-formaldehyde and 1-naphthol-formaldehyde polymeric compounds | |
Desideri et al. | In vitro evaluation of the anti-picornavirus activities of new synthetic flavonoids | |
US4327088A (en) | Phosphonooxy- or glycosyloxy-substituted acrylophenones, compositions and uses thereof | |
JPH03271224A (en) | Carcinostatic agent | |
Houghton | Chromone alkaloids | |
Crouch et al. | Alkaloids from three ethnomedicinal Haemanthus species: H. albiflos, H. deformis and H. pauculifolius (Amaryllidaceae) | |
KR100377514B1 (en) | Chalcone derivatives, method for preparation thereof and pharmaceutical composition containing the said derivatives | |
US5753695A (en) | Flavilium compounds and method of using | |
JP3740284B2 (en) | Novel compound having antimalarial activity or salt thereof | |
JPH0625213A (en) | Flavone derivative | |
PL106887B1 (en) | METHOD OF MANUFACTURE OF NEW 1-SULFONYLO-5/6 / -SUBSTABLED BENZIMIDAZOLA | |
EP1322632A1 (en) | N-disubstituted carbamoyloxy flavones | |
AU621430B2 (en) | Aroyloxy alkanols as anti-retrovirus agents | |
JP2907948B2 (en) | New steroid compounds and anticancer drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKLA | Lapsed |